Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that Dapagliflozin, as a highly selective SGLT-2 inhibitor,38 may have the ability to influence the function of central autonomic control that results in neural activation related to BP and HR regulation.”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [38]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Kidney: Physiology and Pathophysiology
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-6-544_3 · Cited by 1,673
Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
Saydah, S. H. (2004) · JAMA · doi:10.1001/jama.291.3.335 · Cited by 1,357
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
Wood, I. S., & Trayhurn, P. (2003) · British Journal of Nutrition · doi:10.1079/bjn2002763 · Cited by 889
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Diabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716
Kanai, Y., Lee, W. S., You, G., Brown, D., & Hediger, M. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116972 · Cited by 630
Renal Na+-glucose cotransporters
Wright, E. M. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.1.f10 · Cited by 583
Research works printed but not linked: 17
- Washburn W., 2007, 234th National ACS Meeting
- 2006, Diabetes Atlas
- Bertoni A. G., 2007, Diabetes Care
- Mueller G., 2002, Recent Res. Develop. Endocrinol., 3, 199
- Moe O. W., 2000, The Kidney, 375
- Wright E. M., 1993, Soc. Gen. Physiol. Ser., 48, 229
- Wright E. M., 1992, Acta Physiol. Scand., Suppl., 146, 201
- Wells R. G., 1992, Am. J. Physiol., 263, F459
- Santer R., 2000, J. Inher. Metab. Dis., 23, 178
- 2004, Chem. Abstr., 142, 94061
- 2004, Chem. Abstr., 141, 332411
- 2004, Chem. Abstr., 141, 123854
- 2003, Chem. Abstr., 138, 153771
- 2001, Chem. Abstr., 135, 273164
- 2001, Chem. Abstr., 135, 273163
- 2003, Chem. Abstr., 138, 221784
- 2004, Chem. Abstr., 141, 89317
Cited by
Items 101–200 of 684
SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
Saucedo‐Orozco, H., Voorrips, S. N., Yurista, S. R., de Boer, R. A., & Westenbrink, B. D. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.1.1 · Cited by 113
Nguyen, T., Wen, S., Gong, M., Yuan, X., Xu, D., Wang, C., Jin, J., & Zhou, L. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s258593 · Cited by 97
Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus
Plosker, G. L. (2012) · Drugs · doi:10.2165/11209910-000000000-00000 · Cited by 101
“for human SGLT1, the major transporter in the gut responsible for glucose absorption.([18]) The 50% inhibitory concentrations of dapagliflozin for human SGLT2 and SGLT1 were 1.”
Synthetic Strategies toward SGLT2 Inhibitors
Aguillón, A. R., Mascarello, A., Segretti, N., de Azevedo, H. F. Z., Guimarães, C. R. W., Miranda, L. S. M., & de Souza, R. O. M. A. (2018) · Organic Process Research & Development · doi:10.1021/acs.oprd.8b00017 · Cited by 103
SGLT2 inhibitors: their potential reduction in blood pressure
Maliha, G., & Townsend, R. R. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.11.001 · Cited by 97
“The relative innocuousness of the condition provided the biochemical inspiration for SGLT2 inhibitor development (21).”
BackgroundStructural selectivity of human SGLT inhibitors
Hummel, C. S., Lu, C., Liu, J., Ghezzi, C., Hirayama, B. A., Loo, D. D. F., Kepe, V., Barrio, J. R., & Wright, E. M. (2012) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00328.2011 · Cited by 94
“The phenol-aglycone of dapagliflozin [4-chloro3-(4-ethoxybenzyl)phenol] was obtained by hydrolysis of the corresponding bromo-aglycone, prepared from commercial 4-bromo-2chlorobenzoic acid (28).”
BackgroundMethodResultInfluentialKasichayanula, S., Liu, X., Zhang, W., Pfister, M., LaCreta, F. P., & Boulton, D. W. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.011 · Cited by 94
Kasichayanula, S., Liu, X., Shyu, W. C., Zhang, W., Pfister, M., Griffen, S. C., Li, T., LaCreta, F. P., & Boulton, D. W. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01314.x · Cited by 93
“Thus, the insulin-independent mechanism of action of dapagliflozin does not overlap with that of metformin, and the two drugs represent a potentially attractive oral combination therapy for patients with T2DM.”
BackgroundInfluentialAn In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
Lin, S., Larrue, C., Scheidegger, N. K., Seong, B. K. A., Dharia, N. V., Kuljanin, M., Wechsler, C. S., Kugener, G., Robichaud, A. L., Conway, A. S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1851 · Cited by 94
Sha, S., Polidori, D., Farrell, K., Ghosh, A., Natarajan, J., Vaccaro, N. M., Pinheiro, J. C., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12418 · Cited by 90
Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors
Blaschek, W. (2017) · Planta Medica · doi:10.1055/s-0043-106050 · Cited by 96
“1), a C-glycoside analog with high SGLT2 selectivity, was published [17].”
BackgroundWhat does sodium‐glucose co‐transporter 1 inhibition add: Prospects for dual inhibition
Rieg, J. A. D., & Rieg, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13630 · Cited by 92
Recent and emerging anti‐diabetes targets
Mohler, M. L., He, Y., Wu, Z., Hwang, D., & Miller, D. D. (2008) · Medicinal Research Reviews · doi:10.1002/med.20142 · Cited by 93
“Monodifluorophosphonate derivatives also have been described (141)(272) (Fig.”
BackgroundApplication of carbohydrates in approved small molecule drugs: A review
Jiang, H., Qin, X., Wang, Q., Xu, Q., Wang, J., Wu, Y., Chen, W., Wang, C., Zhang, T., Xing, D., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113633 · Cited by 94
From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
Bays, H. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802710422 · Cited by 83
Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents
Washburn, W. N. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903337828 · Cited by 83
“1 nM; selectivity versus hSGLT1 is 1200 [30].”
Self-citationA Fluorescence Method for Measurement of Glucose Transport in Kidney Cells
Blodgett, A. B., Kothinti, R. K., Kamyshko, I., Petering, D. H., Kumar, S. N., & Tabatabai, N. M. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0041 · Cited by 83
“Also, the in vitro effectiveness of new antidiabetes drugs such as dapagliflozin and sergliflozin-A, which target SGLT2 activity, were investigated for their abilities to inhibit [(14)C]AMG transport.(26,27) We also were using [(14)C]AMG to measure SGLT activity in LLC-PK1 and PMKCs.”
Washburn, W. N., & Poucher, S. M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.774372 · Cited by 87
“3 1,200 1,200 610 190,000 7,600 3,000 680 210 1,100 1,300 [89] [16] [43] 5 25 167 705 None [91]”
Self-citationYang, Z., Li, T., Xian, J., Chen, J., Huang, Y., Zhang, Q., Lin, X., Lu, H., & Lin, Y. (2022) · The FASEB Journal · doi:10.1096/fj.202200243r · Cited by 79
Dobbins, R. L., O’Connor‐Semmes, R., Kapur, A., Kapitza, C., Golor, G., Mikoshiba, I., Tao, W., & Hussey, E. K. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01462.x · Cited by 80
Shibazaki, T., Tomae, M., Ishikawa-Takemura, Y., Fushimi, N., Itoh, F., Yamada, M., & Isaji, M. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.193045 · Cited by 84
“For instance, dapagliflozin and remogliflozin, respectively, have 1200- and 365-fold specificity for SGLT2 versus SGLT1 (Fujimori et al., 2008; Meng et al., 2008).”
BackgroundGoodwin, N. C., Mabon, R., Harrison, B. A., Shadoan, M. K., Almstead, Z. Y., Xie, Y., Healy, J. P., Buhring, L., DaCosta, C. M., Bardenhagen, J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900951n · Cited by 78
The effect of dapagliflozin on renal function in patients with type 2 diabetes
Kohan, D. E., Fioretto, P., Johnsson, K. M., Parikh, S. J., Ptaszynska, A., & Ying, L. (2016) · Journal of Nephrology · doi:10.1007/s40620-016-0261-1 · Cited by 82
“Dapagliflozin is a potent and highly selective SGLT2 inhibitor [4].”
BackgroundLight-Mediated Cross-Coupling of Anomeric Trifluoroborates
Miller, E. M., & Walczak, M. A. A. (2021) · Organic Letters · doi:10.1021/acs.orglett.1c01035 · Cited by 78
Zhang, W., Welihinda, A. A., Mechanic, J., Ding, H., Zhu, L., Lu, Y., Deng, Z., Sheng, Z., Lv, B., Chen, Y., et al. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.01.001 · Cited by 79
Lee, J., Lee, S.-H., Seo, H. J., Son, E., Lee, S., Jung, M. E., Lee, M., Han, H.-K., Kim, J., Kang, J., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.073 · Cited by 77
Luippold, G., Klein, T., Mark, M., & Grempler, R. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01569.x · Cited by 76
“In a rodent model of T1DM, the SGLT-2 inhibitors, dapagliflozin [14,15], sergliflozin [17] and TS-071 [19] have been reported to reduce hyperglycaemia.”
BackgroundGhouilem, J., Tran, C., Grimblat, N., Retailleau, P., Alami, M., Gandon, V., & Messaoudi, S. (2021) · ACS Catalysis · doi:10.1021/acscatal.0c05052 · Cited by 80
Wu, Y., & Meanwell, N. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00790 · Cited by 77
Medicinal Chemistry Strategies for the Modification of Bioactive Natural Products
Ding, Y., & Xue, X. (2024) · Molecules · doi:10.3390/molecules29030689 · Cited by 88
Strojek, K., Yoon, K.-H., Hruba, V., Sugg, J., Langkilde, A. M., & Parikh, S. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0072-0 · Cited by 74
Dapagliflozin-citric acid cocrystal showing better solid state properties than dapagliflozin
Deng, J.-H., Lu, T., Sun, C. C., & Chen, J. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.04.008 · Cited by 75
No direct effect of SGLT2 activity on glucagon secretion
Kuhre, R. E., Ghiasi, S. M., Adriaenssens, A. E., Albrechtsen, N. J. W., Andersen, D. B., Aivazidis, A., Chen, L., Mandrup-Poulsen, T. R., Ørskov, C., Gribble, F. M., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4849-6 · Cited by 76
Michel, M. C., Mayoux, E., & Vallon, V. (2015) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-015-1134-1 · Cited by 78
“…and diabetic Tallyho/JngJ mice (Neschen et al. 2015) and with dapagliflozin in insulin-resistant mice (Bonner et al. 2015) and in diabetic patients (Merovici et al. 2014), a single dose or a 4-week treatment with empagliflozin increased endogenous glucose production accompanied by elevated plasma…”
BackgroundDapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule
Ghezzi, C., Yu, A. S., Hirayama, B. A., Kepe, V., Liu, J., Scafoglio, C., Powell, D. R., Huang, S.-C., Satyamurthy, N., Barrio, J. R., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016050510 · Cited by 71
Kalgutkar, A. S. S., Tugnait, M., Zhu, T., Kimoto, E., Miao, Z., Mascitti, V., Yang, X., Tan, B., Walsky, R. L., Chupka, J., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040675 · Cited by 71
Huard, K., Brown, J. A., Jones, J. E. C., Cabral, S., Futatsugi, K., Gorgoglione, M. F., Lanba, A., Vera, N. B., Zhu, Y., Yan, Q., et al. (2015) · Scientific Reports · doi:10.1038/srep17391 · Cited by 72
Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
Beitelshees, A. L., Leslie, B. R., & Taylor, S. I. (2019) · Diabetes · doi:10.2337/dbi18-0006 · Cited by 78
“Washburn and colleagues (16) extended the half-life by removing oxygen from the glycosidic linkage connecting the sugar and aglycone moieties, a modification that is incorporated in all currently approved SGLT2 inhibitors.”
BackgroundSwe, M. T., Thongnak, L., Jaikumkao, K., Pongchaidecha, A., Chatsudthipong, V., & Lungkaphin, A. (2019) · Clinical Science · doi:10.1042/cs20190863 · Cited by 73
Shaikh, S., Rizvi, S. M. D., Shakil, S., Riyaz, S., Biswas, D., & Jahan, R. (2016) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1319 · Cited by 70
Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin
Kasichayanula, S., Liu, X., Griffen, S. C., LaCreta, F. P., & Boulton, D. W. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12024 · Cited by 70
“Dapagliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor [1] that lowers blood glucose through a reduction in renal glucose reabsorption and an increase in urinary glucose excretion (UGE) [2].”
BackgroundCardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
Rabizadeh, S., Nakhjavani, M., & Esteghamati, A. (2019) · Intern J Endocrinol Metab · doi:10.5812/ijem.84353 · Cited by 81
“Empagliflozin has a higher selectivity for SGLT2 than for SGLT1 (2700 folds) (17).”
BackgroundInfluentialAubry, A., Gu, H., Magnier, R., Morgan, L., Xu, X., Tirmenstein, M. A., Wang, B., Deng, Y., Cai, J., Couerbe, P., et al. (2010) · Bioanalysis · doi:10.4155/bio.10.139 · Cited by 69
Sakamoto, K., Nagai, M., Ebe, Y., Yorimitsu, H., & Nishimura, T. (2019) · ACS Catalysis · doi:10.1021/acscatal.8b04686 · Cited by 74
Hamouda, N. N., Sydorenko, V., Qureshi, M. A., Alkaabi, J., Öz, M., & Howarth, F. C. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2262-5 · Cited by 68
“6 h [18].”
Chen, L., & Leung, P. S. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12064 · Cited by 72
“C-aryl glucosides with meta-substituted diarylmethanes, such as dapagliflozin (figure 1g), appear to bind SGLT2 better than their biphenyl and 1,2-diarylethane counterparts [27].”
BackgroundXie, K., Zhang, X., Sui, S., Ye, F., & Dai, J. (2020) · Nature Communications · doi:10.1038/s41467-020-18990-9 · Cited by 66
Maccari, R., & Ottanà, R. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00867 · Cited by 78
Xu, G. Z., Lv, B., Roberge, J. Y., Xu, B., Du, J., Dong, J., Chen, Y., Peng, K., Zhang, L., Tang, X., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401780b · Cited by 65
Goodwin, N. C., Ding, Z., Harrison, B. A., Strobel, E. D., Harris, A. L., Smith, M. G., Thompson, A. Y., Xiong, W., Mseeh, F., Bruce, D., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01541 · Cited by 74
Cai, X., Ji, L., Chen, Y., Yang, W., Zhou, L., Han, X., Zhang, S., & Ji, L. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12625 · Cited by 66
Reilly, T. P., Graziano, M. J., Janovitz, E. B., Dorr, T. E., Fairchild, C. R., Lee, F. Y., Chen, J., Wong, T., Whaley, J. M., & Tirmenstein, M. A. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0053-3 · Cited by 63
“Dapagliflozin is a small-molecule inhibitor of SGLT2 [3, 4] that has been shown to be highly selective for SGLT2 compared with other SGLT family members and to have no off-target interactions in an in vitro screen of more than 330 receptors, enzymes, ion channels, and transporters [14].”
Self-citationKasichayanula, S., Chang, M., Liu, X., Shyu, W.-C., Griffen, S. C., LaCreta, F. P., & Boulton, D. W. (2012) · Advances in Therapy · doi:10.1007/s12325-011-0098-x · Cited by 63
“Dapagliflozin is a first-in-class oral, selective, reversible inhibitor of SGLT2 in development for the treatment of T2DM [9].”
Feijóo‐Bandín, S., Aragón‐Herrera, A., Otero-Santiago, M., Anido‐Varela, L., Moraña‐Fernández, S., Tarazón, E., Roselló‐Lletí, E., Portolés, M., Gualillo, O., González‐Juanatey, J. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105634 · Cited by 63
“~1200 fold [86] EMA-2012 [87] FDA-2020 [88] FDA-2021 [89] T2DM [87] HFrEF [88] CKD [89]”
Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats
Kapoor, S., Rodríguez, D., Riwanto, M., Edenhofer, I., Segerer, S., Mitchell, K. J., & Wuthrich, R. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125603 · Cited by 66
In the Search of Glycoside-Based Molecules as Antidiabetic Agents
Pałasz, A., Cież, D., Trzewik, B., Miszczak, K., Tynor, G., & Bazan, B. (2019) · Topics in Current Chemistry · doi:10.1007/s41061-019-0243-6 · Cited by 66
ElMahdy, M. K., Helal, M. G., & Ebrahim, T. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106730 · Cited by 63
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors
Ugusman, A., Kumar, J., & Aminuddin, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107832 · Cited by 64
Yang, W., Ma, J., Li, Y., Li, Y., Zhou, Z., Kim, J. H., Zhao, J., & Ptaszynska, A. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12634 · Cited by 60
“Sodium–glucose cotransporter 2 (SGLT2) inhibitors have an insulin-independent mechanism of action, inhibiting renal glucose reabsorption and increasing glucosuria, thereby reducing hyperglycemia.(8) This glucosuria is associated with caloric elimination, possibly leading to weight loss, and the osmotic diuresis and na…”
BackgroundEllsworth, B. A., Meng, W., Patel, M. M., Girotra, R. N., Wu, G., Sher, P. M., Hagan, D. L., Obermeier, M. T., Humphreys, W. G., Robertson, J. G., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.109 · Cited by 58
Self-citationRenal glucose transporters: novel targets for hyperglycemia management
Mather, A., & Pollock, C. A. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.38 · Cited by 58
“These effects have also been reported to occur without provoking hypoglycemia in diabetic Sprague–Dawley rats”
BackgroundHardman, T. C., & Dubrey, S. W. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0004-1 · Cited by 57
Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets
Saponaro, C., Mühlemann, M., Acosta-Montalvo, A., Piron, A., Gmyr, V., Delalleau, N., Moerman, E., Thévenet, J., Pasquetti, G., Coddeville, A., et al. (2020) · Diabetes · doi:10.2337/db19-0888 · Cited by 60
“95%), at the steady state, the free fraction is only 4% in man (33).”
BackgroundVeltkamp, S. A., Kadokura, T., Krauwinkel, W. J. J., & Smulders, R. A. (2011) · Clinical Drug Investigation · doi:10.1007/bf03256922 · Cited by 55
Sodium–glucose transport: role in diabetes mellitus and potential clinical implications
Vallon, V., & Sharma, K. (2010) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32833bec06 · Cited by 57
Glycogen phosphorylase inhibitors: a patent review (2013 - 2015)
Donnier‐Maréchal, M., & Vidal, S. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1131268 · Cited by 61
A computational model of epithelial solute and water transport along a human nephron
Layton, A. T., & Layton, H. E. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006108 · Cited by 55
Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors
Kang, S. Y., Song, K., Lee, J., Lee, S.-H., & Lee, J. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.076 · Cited by 55
Cai, W., Jiang, L., Xie, Y., Liu, Y., Liu, W., & Zhao, G. (2015) · Medicinal Chemistry · doi:10.2174/1573406411666150105105529 · Cited by 58
Wrzesinski, K., & Fey, S. J. (2018) · Bioengineering · doi:10.3390/bioengineering5010022 · Cited by 61
“BCCIPβ plays a role in cell growth regulation [119].”
BackgroundZafar, A., Elbagory, I., Alruwaili, N. K., Imam, S. S., Alomar, F. A., Elkomy, M. H., Ahmad, N., & Elmowafy, M. (2019) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2019.1667820 · Cited by 54
“Also, the vehicles used in the formulation modulate the P-gp efflux pumps and/or CYP450 enzymes function at the intestine region and improve the absorption of the drug.([28,29])”
BackgroundZhou, X., Ding, H., Chen, P., Liu, L., Sun, Q., Wang, X., Wang, P., Lv, Z., & Li, M. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201914557 · Cited by 54
Synthesis and SAR of Benzisothiazole- and Indolizine-β- d -glucopyranoside Inhibitors of SGLT2
Zhou, H., Danger, D. P., Dock, S. T., Hawley, L. B., Roller, S. G., Smith, C. D., & Handlon, A. L. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml900010b · Cited by 55
Ikegai, K., Imamura, M., Suzuki, T., Nakanishi, K., Murakami, T., Kurosaki, E., Noda, A., Kobayashi, Y., Yokota, M., Koide, T., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.03.067 · Cited by 52
The Na+/glucose cotransporters: from genes to therapy
Silva, R. S., Mori, R. C. T., David-Silva, A., Okamoto, M. M., Freitas, H. S., & Machado, U. F. (2010) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2010007500115 · Cited by 59
“Dapagliflozin administration to diabetic rats resulted in a 55% reduction in blood glucose 5 h after a single dose (58).”
BackgroundThe importance of synthetic drugs for type 2 diabetes drug discovery
Safavi, M., Foroumadi, A., & Abdollahi, M. R. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.837883 · Cited by 60
“1 C-glycoside analogues of SGLT2 inhibitors Many C-aryl glycoside analogues containing conjugated aryl moiety with glucose moiety by C--C bond instead of instable C--O--C bond have been designed and synthesized [179,214].”
BackgroundOmotuyi, O. I., Nash, O., Inyang, O. K., Ogidigo, J. O., Enejoh, O. A., Okpalefe, O. A., & Hamada, T. (2018) · 3 Biotech · doi:10.1007/s13205-018-1138-x · Cited by 58
“2009), glucagon-like peptide 1 (GLP1) receptor (Drucker and Nauck 2006), renal sodium dependent glucose transporter (SGLUT)-1/2 (Meng et al. 2008) and nucleotide oligomerization domain (NOD)-1/2 (Shiny et al.”
BackgroundInfluentialCherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 55
Nomura, S., Yamamoto, Y., Matsumura, Y., Ohba, K., Sakamaki, S., Kimata, H., Nakayama, K., Kuriyama, C., Matsushita, Y., Ueta, K., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400339b · Cited by 52
Synthetic approaches to the 2012 new drugs
Ding, H. X., Leverett, C. A., Kyne, R. E., Liu, K. K. ‐., Sakya, S. M., Flick, A. C., & O’Donnell, C. J. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.017 · Cited by 52
Yao, C., Song, J., Chen, C., Yeh, T., Hsieh, T.-C., Wu, S., Huang, C.-Y., Huang, Y.-L., Wang, M., Liu, Y.-W., et al. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.06.053 · Cited by 51
Shah, N. K., Deeb, W. E., Choksi, R., & Epstein, B. J. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1010 · Cited by 53
Henschke, J. P., Lin, C., Wu, P., Tsao, W.-S., Liao, J., & Chiang, P. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b00601 · Cited by 58
Yao, C., Song, J., Chen, C., Yeh, T., Hung, M., Chang, C., Liu, Y., Yuan, M.-C., Hsieh, C., Huang, C.-Y., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101072y · Cited by 50
SGLT2 inhibition and glucagon secretion in humans
Saponaro, C., Pattou, F. N., & Bonner, C. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.06.005 · Cited by 57
Convenient Synthesis of 3‐Glycosylated Isocoumarins
Sudarshan, K., & Aidhen, I. S. (2016) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201601264 · Cited by 49
Rodríguez, D., Kapoor, S., Edenhofer, I., Segerer, S., Riwanto, M., Kipar, A., Yang, M., Mei, C., & Wuthrich, R. P. (2015) · Kidney & Blood Pressure Research · doi:10.1159/000368540 · Cited by 53
Chiang, H., Lee, J., Huang, H., Huang, H. Y., Liu, H., & Huang, C. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14859 · Cited by 52
Ender, S. A., Machner, A., Pap, G., Hubbe, J., Graßhoff, H., & Hw, N. (2007) · Acta Orthopaedica · doi:10.1080/17453670710014301 · Cited by 48
Carbohydrate-Based Therapeutics
Mishra, S., Upadhaya, K., Mishra, K. B., Shukla, A. K., Tripathi, R. P., & Tiwari, V. K. (2016) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63601-0.00010-7 · Cited by 49
Schmölzer, K., Lemmerer, M., & Nidetzky, B. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26491 · Cited by 48
“They therefore excel in biological stability and so, generally, in longterm efficacy during application (Lee et al., 2010; Meng et al., 2008).”
BackgroundKim, M. J., Lee, J., Kang, S. Y., Lee, S.-H., Son, E., Jung, M. E., Lee, S., Song, K., Lee, M., Han, H.-K., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.006 · Cited by 47
de Leeuw, A. E., & de Boer, R. A. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw009 · Cited by 46
“An ideal target for reducing hyperglycaemia by inducing glycosuria should be selective, safe, and well tolerated.(12,23)”
BackgroundBernhardson, D. J., Brandt, T. A., Hulford, C. A., Lehner, R. S., Preston, B. R., Price, K. E., Sagal, J. F., Pierre, M. J. S., Thompson, P. H., & Thuma, B. A. (2014) · Organic Process Research & Development · doi:10.1021/op400289z · Cited by 46
Remote C−H Glycosylation by Ruthenium(II) Catalysis: Modular Assembly ofmeta‐C‐Aryl Glycosides
Wu, J., Kaplaneris, N., Pöhlmann, J., Michiyuki, T., Yuan, B., & Ackermann, L. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202208620 · Cited by 45
Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 Inhibitors
Song, K., Lee, S., Kim, M. J., Seo, H. J., Lee, J., Lee, S.-H., Jung, M. E., Son, E., Lee, M., Kim, J., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100256c · Cited by 45
Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis
Kang, Y.-X., Zhan, F., He, M., Liu, Z., & Song, X. (2020) · Vascular Pharmacology · doi:10.1016/j.vph.2020.106779 · Cited by 47
SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus
Misra, M. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01574.x · Cited by 45
Discovery of non-glucoside SGLT2 inhibitors
Li, A., Zhang, J., Greenberg, J., Lee, T. W., & Liu, J. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.02.056 · Cited by 44
Robinson, R. P., Mascitti, V., Boustany, C., Carr, C. L., Foley, P. M., Kimoto, E., Leininger, M. T., Lowe, A., Klenotic, M. K., MacDonald, J. I., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.075 · Cited by 44
Metadata
- Authors
- Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., Zahler, R., Deshpande, P. P., Pullockaran, A., Hagan, D. L., Morgan, N., Taylor, J. R., Obermeier, M. T., Humphreys, W. G., Khanna, A., Discenza, L., Robertson, J. G., Wang, A., Han, S., Wetterau, J. R., Janovitz, E. B., Flint, O. P., Whaley, J. M., & Washburn, W. N.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Metabolic Diseases Chemistry, Process R & D, Metabolic Diseases Biology, Pharmacological Candidate Optimization, Drug Safety Evaluation, Research and Development, Bristol-Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543
- Corresponding author
- Meng, Wei
- Washburn, William N.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-02-09
- Volume
- 51
- Issue
- 5
- Pages
- 1145-1149
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2026609170
- Cited by
- 634
- References
- 39
- Citations by year
- 2026: 32 · 2025: 35 · 2024: 28 · 2023: 23 · 2022: 35 · 2021: 32 · 2020: 40 · 2019: 34 · 2018: 26 · 2017: 22 · 2016: 35 · 2015: 44 · 2014: 40 · 2013: 36 · 2012: 43
- FWCI
- 35.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, antidiabetic drug discovery, blood glucose reduction, streptozotocin-induced hyperglycemia, ADME properties
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Administration, Oral, Animals, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Glucosides, Humans, Hypoglycemic Agents, Kidney, Stereoisomerism, Sodium-Glucose Transporter 2, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.